The National Commission into the Regulation of AI in Healthcare has today, 10 September 2026, released its recommendations for strengthening the regulation of AI in UK healthcare. The aim is to ensure AI remains safe, keeps pace with innovation, and maintains public trust.
Among the key proposals, the Commission suggests that the Medicines and Healthcare products Regulatory Agency (MHRA) introduce staged authorisations for new AI models. This approach, likened to 'L-plates' for learner drivers, would allow new models to be deployed under close supervision to demonstrate real-world safety before receiving fuller authorisation. This is intended to give UK patients early access to promising new models while carefully controlling risks.
The report also recommends continuous, real-world monitoring for AI-enabled medical devices throughout their operational life. This reflects the evolving nature of AI technologies after deployment, ensuring patient protection and enabling regulators to act swiftly if issues arise. Additionally, the Commission advises that the public should have easy access to information regarding the safety of specific AI-enabled medical devices, including any adverse incidents.
The independent Commission, established by the MHRA in September 2025, gathered evidence from over 12,000 people, including patients, clinicians, and industry developers. This engagement revealed broad public support for AI in healthcare, provided there are strong safety standards, meaningful human oversight, and transparency about its use in care. The government and the MHRA will now consider these recommendations, with a formal response expected in due course.